Skip to main content
Clinical Trials/NCT05308277
NCT05308277
Recruiting
Not Applicable

Engineering Validation of Leo Device to Assess Clinical Control of Children Recovering From Acute Asthma Exacerbation

ResMed1 site in 1 country30 target enrollmentStarted: April 27, 2022Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
ResMed
Enrollment
30
Locations
1
Primary Endpoint
CASI questionnaire

Overview

Brief Summary

This is a prospective, observational study to investigate the agreement of the Leo device signal derivation with gold standard asthmatic testing in recently exacerbated asthmatic children.

This study is designed for engineering validation of a wireless, wearable device (Leo) for assessing clinical control of children recovering from acute respiratory event such as asthma attack. The Leo device will monitor chest impedance, ECG and body position to calculate parameters such as respiration rate, heart rate, lung volume, tidal breathing flow and volume curves, and body position. These parameters will then be used to train and algorithm to assess clinical control of asthma.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
2 Years to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Children aged ≥2 years old and \<18 years old at time of consent
  • Children with a legal guardian able to sign consent for study participation
  • Children and caregivers able to read and understand English or Spanish
  • Children who are currently hospitalized with acute exacerbation of asthma
  • Child's caregiver is able to communicate using SMS
  • Child has an asthma inhaler

Exclusion Criteria

  • Children with complex medical conditions which may hinder their ability to complete protocol assessments
  • Children with an active skin condition involving the area on the chest wall where the Leo device will be attached. E.g. inflamed and/or infected eczema or other skin conditions involving the anterior chest wall at the time of recruitment
  • Children with any implanted medical devices, E.g. cardiac pacemaker
  • Children with any history of known allergic reaction to adhesives or hydrogels, as the ones used with the Leo device

Outcomes

Primary Outcomes

CASI questionnaire

Time Frame: Baseline visit and 7 days post hospital/ED discharge

Questionnaire will be used to determine asthma severity during baseline and follow-up visit. CASI scores include five domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. Range is from 0 -17, with a higher score indicating worse asthma severity

Asthma Flare-up diary

Time Frame: Follow-up for 7 days post hospital/ED discharge

Self-reported asthma flare-up diary score will be measured daily during the remote (at home) period in between visits.

Airway resistance through oscillometry test

Time Frame: Baseline visit and 7 days post hospital/ED discharge

Asthma severity measures will be determined through oscillometry test at baseline and follow-up visit. Leo measurements will be assessed for agreement with oscillometry measures.

Secondary Outcomes

  • Inhaler usage(Follow-up for 7 days post hospital/ED discharge)
  • Tidal breathing from PNT device(7 days post hospital/ED discharge)

Investigators

Sponsor
ResMed
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials